Stephan Dixon, MD
Glaucoma Specialist · Cincinnati, OHNPI 1396125589
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Alcon at 42.5% of the total. 2025 is the largest year on record at $52,241, more than ten times the $741 reported in 2019.
Across 413 payments — averaging $198.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$35K
- AbbVie$21K
- Glaukos Corporation$14K
- Alcon Research LLC$3K
- Ivantis, Inc$2K
- NEW World Medical,inc.$2K
- plus $4K from 22 others
Across 1 payment — averaging $800.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$800
What the payments were for
- Consulting fees$17,89222%
- Speaking & faculty fees$43,56353%
- Travel & lodging$6,2088%
- Food & beverage$14,22817%
- Other$1170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 129 | $34,891 |
| AbbVie(2 entities) | 130 | $21,452 |
| Glaukos Corporation | 12 | $13,953 |
| Alcon Research LLC | 2 | $3,267 |
| Ivantis, Inc | 11 | $2,331 |
| NEW World Medical,inc. | 21 | $1,971 |
| Johnson & Johnson Surgical Vision, Inc. | 18 | $767 |
| Sight Sciences, Inc. | 8 | $503 |
| Carl Zeiss Meditec USA, Inc. | 2 | $319 |
| Halozyme Inc | 17 | $304 |
| Ocular Therapeutix, Inc. | 9 | $268 |
| Tarsus Pharmaceuticals, Inc. | 6 | $264 |
| Rxsight Inc | 3 | $259 |
| Bausch & Lomb Americas Inc. | 7 | $224 |
| Thea Pharma Inc. | 8 | $180 |
| Harrow Eye, LLC | 2 | $169 |
| Eyevance Pharmaceuticals LLC | 2 | $153 |
| Dompe US, Inc. | 1 | $112 |
| Mallinckrodt Enterprises LLC | 1 | $104 |
| Amgen(2 entities) | 6 | $99 |
| Aerie Pharmaceuticals, Inc. | 6 | $96 |
| Lensar, Inc. | 1 | $75 |
| Regeneron Healthcare Solutions, Inc. | 2 | $74 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $52 |
| Rayner Intraocular Lenses Limited | 2 | $41 |
| Sun Pharmaceutical Industries Inc. | 1 | $28 |
| Novartis | 2 | $27 |
| Biotissue Holdings Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$36,540
- Voyager DSLT$18,422
- XEN GLAUCOMA TREATMENT SYSTEM$18,083
- Travoprost Intraocular Implant - iDose$10,904
- Kahook Dual Blade$1,666
- Ahmed Glaucoma Valve$1,666
- Clearpath$1,541
- Streamline$1,541
- Via360$1,216
- Centurion$1,012
- ARGOS$865
- Clareon$865
- DURYSTA$724
- RXSIGHT CONTACT LENS$245
- RXSIGHT INJECTOR CARTRIDGE$245
- RXSIGHT INJECTOR HANDPIECE$245
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$245
- OMNI(R) SURGICAL SYSTEM (US)$235
- QUATERA 700$202
- Wavelight$150
How this compares
Too few glaucoma specialist providers in Ohioto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 279 | $142,015 |
| LumiganBimatoprost | 269 | $111,403 |
| RhopressaNetarsudil Mesylate | 138 | $59,119 |
| RestasisCyclosporine | 38 | $32,109 |
| CombiganBrimonidine Tartrate/Timolol | 94 | $31,475 |
| Prednisolone Acetate | 325 | $12,801 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 862 | $12,598 |
| Latanoprost | 1,558 | $12,251 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 39 | $8,814 |
| VyzultaLatanoprostene Bunod | 17 | $7,556 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 66 | $6,454 |
| Travoprost | 38 | $4,088 |
| Brimonidine Tartrate | 354 | $2,647 |
| Brinzolamide | 37 | $2,517 |
| Timolol Maleate | 332 | $2,176 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $96 | $201,135417 claims |
| AbbVieLumigan, Restasis, Combigan | $21,452 | $174,987401 claims |
| AlconSimbrinza | $34,891 | $8,81439 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $224 | $7,55617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Ohioon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Cincinnati
- Mary QiuCleveland$99K
- Shalini SoodIndependence$30K
- Shelly JainColumbus$11K
- Mark SlabaughColumbus$3K
- Gloria FlemingColumbus$2K
- Emily RossColumbus$1K
- Paul WeberColumbus$47
- Sayoko MoroiColumbus$28
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.